CAMBRIDGE, Mass., Jan. 12, 2024 – Arena BioWorks announces its inauguration as a leading-edge biomedical research institute. With its mission firmly rooted in deciphering the mechanisms of human diseases and propelling technological innovations, Arena BioWorks is poised to transform these insights into lifesaving therapeutics through its internal biotech companies.
Co-Founders and Visionaries
The foundation of Arena BioWorks is underpinned by a distinguished group of co-founders. Stuart Schreiber, a renowned scientist from Harvard University and co-founder of the Broad Institute, joins forces with Steve Pagliuca, former Co-Chair of Bain Capital, and Tom Cahill of Newpath Partners, a life science venture capital firm. This trio brings a blend of scientific acumen and visionary leadership to the institute.
Core Scientific Team
The scientific endeavors at Arena BioWorks are spearheaded by leaders in their respective fields. Stuart Schreiber and Keith Joung lead the team, with other eminent scientists set to join. Their expertise in chemical biology and CRISPR gene editing is central to the institute’s innovative research trajectory.
Founding Investors
The institute’s initial phase has been made viable through the substantial backing of Steve Pagliuca, Michael Dell, Michael Chambers, Jim Breyer, and Elisabeth DeLuca. Their support establishes a foundational model for self-sustainability at Arena BioWorks.
Arena’s Novel Approach
Distinct in its operation, Arena BioWorks departs from conventional research models by utilizing a private funding approach. This strategy facilitates a swifter transition from insight discovery to practical application, free from the usual constraints of grant and venture capital dependencies. Arena BioWorks’ research encompasses a broad spectrum of diseases, harnessing a suite of advanced technologies including chemoproteomics, gene editing, and artificial intelligence.
Leadership and Impact
Under the stewardship of Stuart Schreiber, Steve Pagliuca, and Tom Cahill, Arena BioWorks is guided by an amalgamation of expertise in biotechnology, venture capitalism, and scientific innovation. The institute aspires to be a perpetual center of excellence, reinvesting its profits back into ongoing research and development. This innovative model sets a new standard in the biomedical research field.
https://www.nytimes.com/2024/01/12/business/arena-bioworks-scientists-harvard-mit.html
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
![](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)
Plasmids GMP Services
![](https://static.packgene.com/wp-content/uploads/2023/01/10-2.png)
AAV GMP Services
![aav icon](https://static.packgene.com/wp-content/uploads/2023/01/9-1.png)